A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Sponsor: ALX Oncology Inc.
Listed as NCT05002127, this PHASE2/PHASE3 trial focuses on Gastric Adenocarcinoma and Gastric Cancer and remains ongoing. Sponsored by ALX Oncology Inc., it has been updated 12 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2024 — Jul 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2/PHASE3
▶ Show 7 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Feb 2023 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE2_PHASE3
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2022 — May 2022 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Mar 2022 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ALX Oncology Inc.
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Anaheim, United States , Antwerp, Belgium , Badalona, Spain , Barcelona, Spain , Beitou, Taiwan , Besançon, France , Bordeaux, France , Brest, France , Busan, South Korea and 52 more locations